HRP20050432B1 - Novel medicaments for the treatment of chronic obstructive pulmonary diseases - Google Patents

Novel medicaments for the treatment of chronic obstructive pulmonary diseases

Info

Publication number
HRP20050432B1
HRP20050432B1 HR20050432A HRP20050432A HRP20050432B1 HR P20050432 B1 HRP20050432 B1 HR P20050432B1 HR 20050432 A HR20050432 A HR 20050432A HR P20050432 A HRP20050432 A HR P20050432A HR P20050432 B1 HRP20050432 B1 HR P20050432B1
Authority
HR
Croatia
Prior art keywords
alkyl
treatment
chronic obstructive
obstructive pulmonary
pulmonary diseases
Prior art date
Application number
HR20050432A
Other languages
Croatian (hr)
Inventor
Hoenke Christoph
Lustenberger Philipp
Rudolf Klaus
Bouyssou Thierry
Buettner Frank
Konetzki Ingo
Pestel Sabine
Schnapp Andreas
Schollenberger Hermann
Schromm Kurt
Heine Claudia
Original Assignee
Boehringer Ingelheim Pharma Gmbh & Co.Kg.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32185709&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20050432(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma Gmbh & Co.Kg. filed Critical Boehringer Ingelheim Pharma Gmbh & Co.Kg.
Publication of HRP20050432A2 publication Critical patent/HRP20050432A2/en
Publication of HRP20050432B1 publication Critical patent/HRP20050432B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Spojevi opće formule 1naznačeni time, da n je 1; R1 je vodik, halogen, C1-C4-alkil ili -O-C1-C4-alkil; R2 je vodik, halogen, C1-C4-alkil ili -O-C1-C4-alkil; R3 je C1-C4-alkil, OH, halogen, -O-C1-C4-alkil, -O-C1-C4-alkilen-COOH, -O-C1-C4-alkilen-CO-O-C1-C4-alkil, pod uvjetom, da ako R1 i R2 u svakom slučaju predstavljaju orto-metil, R3 ne može biti istovremeno OH. Patent sadrži još 22 patentna zahtjeva.Compounds of general formula I wherein n is 1; R 1 is hydrogen, halogen, C 1 -C 4 -alkyl or -O-C 1 -C 4 -alkyl; R 2 is hydrogen, halogen, C 1 -C 4 -alkyl or -O-C 1 -C 4 -alkyl; R3 is C1-C4-alkyl, OH, halogen, -O-C1-C4-alkyl, -O-C1-C4-alkylene-COOH, -O-C1-C4-alkylene-CO-O-C1-C4-alkyl , provided that if R1 and R2 in each case represent ortho-methyl, R3 cannot be OH at the same time. The patent contains 22 more patent claims.

HR20050432A 2002-11-15 2005-05-13 Novel medicaments for the treatment of chronic obstructive pulmonary diseases HRP20050432B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10253282A DE10253282A1 (en) 2002-11-15 2002-11-15 Treatment of chronic obstructive pulmonary disease, using new or known N-substituted 2-amino-1-(benz-(1,4)-oxazin-3-on-8-yl)-ethanol derivative beta-mimetic agents, suitable for once-daily administration
PCT/EP2003/012565 WO2004045618A2 (en) 2002-11-15 2003-11-11 Novel medicaments for the treatment of chronic obstructive pulmonary diseases

Publications (2)

Publication Number Publication Date
HRP20050432A2 HRP20050432A2 (en) 2006-06-30
HRP20050432B1 true HRP20050432B1 (en) 2012-01-31

Family

ID=32185709

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20050432A HRP20050432B1 (en) 2002-11-15 2005-05-13 Novel medicaments for the treatment of chronic obstructive pulmonary diseases

Country Status (38)

Country Link
EP (2) EP1562603B3 (en)
JP (1) JP4317138B2 (en)
KR (1) KR101092247B1 (en)
CN (3) CN101817800A (en)
AR (2) AR041969A1 (en)
AT (1) ATE430569T1 (en)
AU (1) AU2003285326B2 (en)
BE (1) BE2014C016I2 (en)
BR (1) BRPI0316264B8 (en)
CA (1) CA2506082C (en)
CO (1) CO5570670A2 (en)
CY (2) CY1110500T1 (en)
DE (2) DE10253282A1 (en)
DK (1) DK1562603T3 (en)
EA (1) EA008665B1 (en)
EC (1) ECSP055774A (en)
ES (1) ES2326878T7 (en)
FR (1) FR14C0049I2 (en)
HR (1) HRP20050432B1 (en)
HU (1) HUS1400011I1 (en)
IL (1) IL167900A (en)
LT (1) LTC1562603I2 (en)
LU (1) LU92433I2 (en)
ME (1) ME00354B (en)
MX (1) MXPA05005081A (en)
MY (1) MY136034A (en)
NL (1) NL300650I2 (en)
NO (2) NO334314B1 (en)
NZ (1) NZ540661A (en)
PE (1) PE20040694A1 (en)
PL (1) PL212238B1 (en)
PT (1) PT1562603E (en)
RS (1) RS51607B (en)
SI (1) SI1562603T1 (en)
TW (1) TWI343812B (en)
UA (1) UA81276C2 (en)
WO (1) WO2004045618A2 (en)
ZA (1) ZA200502246B (en)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
DE102004019539A1 (en) * 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg New drugs for the treatment of respiratory diseases
SI1781298T1 (en) * 2004-04-22 2012-04-30 Boehringer Ingelheim Int Pharmaceutical combinations containing benzoxazine for treating respiratory diseases
WO2005110990A1 (en) * 2004-05-13 2005-11-24 Boehringer Ingelheim International Gmbh Hydroxy-substituted benzo-condensed heterocycles for use as beta agonists in the treatment of respiratory diseases
DE102004024452A1 (en) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosol formulation for the inhalation of beta agonists
DE102004024453A1 (en) * 2004-05-14 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg New long-acting bronchodilators for the treatment of respiratory diseases
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
US20050256115A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta-agonists
US7745621B2 (en) 2004-05-14 2010-06-29 Boehringer Ingelheim International Gmbh Long acting bronchodilators for the treatment of respiratory diseases
DE102004024451A1 (en) * 2004-05-14 2005-12-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder formulations for inhalation containing enantiomerically pure beta agonists
DE102004024454A1 (en) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel enantiomerically pure beta agonists, process for their preparation and their use as pharmaceuticals
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
DE102004045648A1 (en) * 2004-09-21 2006-03-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg New betamimetics for the treatment of respiratory diseases
GT200500281A (en) 2004-10-22 2006-04-24 Novartis Ag ORGANIC COMPOUNDS.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
DE102005007654A1 (en) 2005-02-19 2006-08-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg New long-acting betamimetics for the treatment of respiratory diseases
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
DE102005030733A1 (en) * 2005-07-01 2007-01-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg New drug combinations for the treatment of respiratory diseases containing long-acting beta-2 agonists and at least one other active ingredient
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
US7994211B2 (en) 2005-08-08 2011-08-09 Argenta Discovery Limited Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses
MX2008001976A (en) 2005-08-15 2008-03-25 Boehringer Ingelheim Int Method for producing betamimetics.
TWI396541B (en) * 2005-10-10 2013-05-21 Boehringer Ingelheim Int Novel combinations of medicaments for the treatment of respiratory diseases
TWI389692B (en) * 2005-10-10 2013-03-21 Boehringer Ingelheim Int Aerosol formulations for the inhalation of beta-agonists
US7910708B2 (en) 2005-10-21 2011-03-22 Novartis Ag Anti-IL13 human antibodies
CN101296700A (en) * 2005-11-09 2008-10-29 贝林格尔·英格海姆国际有限公司 Aerosolformulation for inhalation
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
CA2642239A1 (en) * 2006-02-16 2007-08-23 Boehringer Ingelheim International Gmbh Drug combinations for the treatment of respiratory tract diseases
PE20080142A1 (en) * 2006-03-15 2008-04-14 Boehringer Ingelheim Int ENANTHOMERICALLY PURE BETA-AGONISTS AND THEIR PREPARATION PROCEDURES
KR20080110925A (en) 2006-04-21 2008-12-19 노파르티스 아게 Purine derivatives for use as adenosin a2a receptor agonists
WO2008017638A1 (en) * 2006-08-07 2008-02-14 Boehringer Ingelheim International Gmbh Single enantiomer beta-agonists, methods for the production thereof and the use thereof as medication
UY30542A1 (en) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int AEROSOL FORMULATION FOR INHALATION OF BETA AGONISTS
UY30543A1 (en) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int AEROSOL FORMULATION FOR INHALATION OF BETA- AGONISTS
DE602007013441D1 (en) 2006-09-29 2011-05-05 Novartis Ag PYRAZOLOPYRIMIDINE AS PI3K LIPID KINASE INHIBITOR
CA2667962A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
DE602007011670D1 (en) 2007-01-10 2011-02-10 Irm Llc COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS
MX2009005813A (en) * 2007-01-25 2009-06-16 Boehringer Ingelheim Int Method for producing betamimetics.
BRPI0811562A2 (en) 2007-05-07 2014-12-09 Novartis Ag ORGANIC COMPOUNDS
EP2231280B1 (en) 2007-12-10 2016-08-10 Novartis AG Amiloride-like Pyrazine-carboxamides as ENaC blockers
PL2231642T3 (en) 2008-01-11 2014-04-30 Novartis Ag Pyrimidines as kinase inhibitors
US8236808B2 (en) 2008-06-10 2012-08-07 Novartis Ag Pyrazine derivatives as ENAC blockers
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
NZ594157A (en) 2008-12-30 2013-07-26 Pulmagen Therapeutics Inflammation Ltd Sulfonamide compounds for the treatment of respiratory disorders
PT2391366E (en) 2009-01-29 2013-02-05 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EP2464649A1 (en) 2009-08-12 2012-06-20 Novartis AG Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
NZ598220A (en) 2009-08-17 2014-02-28 Intellikine Llc Heterocyclic compounds and uses thereof
CA2777245A1 (en) 2009-10-22 2011-04-28 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (en) 2010-09-09 2012-04-30 Irm Llc COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF THE TRK
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
BR112013007469B1 (en) * 2010-09-21 2020-03-31 Intekrin Therapeutics, Inc. SOLID ANTIDIABETIC PHARMACEUTICAL COMPOSITIONS, THEIR USE AND PREPARATION METHOD, METHOD FOR PREPARING A GRANULATION PRODUCT AND PRECURSING PHARMACEUTICAL COMPOSITION
JP2014505088A (en) 2011-02-10 2014-02-27 ノバルティス アーゲー [1,2,4] Triazolo [4,3-b] pyridazine compounds as C-MET tyrosine kinase inhibitors
JP5808826B2 (en) 2011-02-23 2015-11-10 インテリカイン， エルエルシー Heterocyclic compounds and uses thereof
US9102671B2 (en) 2011-02-25 2015-08-11 Novartis Ag Compounds and compositions as TRK inhibitors
UY34305A (en) 2011-09-01 2013-04-30 Novartis Ag DERIVATIVES OF BICYCLIC HETEROCICLES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
UY34329A (en) 2011-09-15 2013-04-30 Novartis Ag TRIAZOLOPIRIDINE COMPOUNDS
ES2558457T3 (en) 2011-09-16 2016-02-04 Novartis Ag Heterocyclic compounds for the treatment of cystic fibrosis
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
EP2755652B1 (en) 2011-09-16 2021-06-02 Novartis AG N-substituted heterocyclyl carboxamides
US9174994B2 (en) 2011-11-23 2015-11-03 Intellikine, Llc Enhanced treatment regimens using mTor inhibitors
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
CN104245701A (en) 2012-04-03 2014-12-24 诺华有限公司 Combination with tyrosine kinase inhibitors and use thereof
EP2906218B1 (en) 2012-10-09 2016-12-14 Boehringer Ingelheim International GmbH Beta-2-adrenoceptor agonist for the treatment of cough
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc Combination of kinase inhibitors and uses thereof
TW201605450A (en) 2013-12-03 2016-02-16 諾華公司 Combination of Mdm2 inhibitor and BRAF inhibitor and their use
BR112016023967A2 (en) 2014-04-24 2017-08-15 Novartis Ag pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
JP6433509B2 (en) 2014-04-24 2018-12-05 ノバルティス アーゲー Aminopyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
WO2015162456A1 (en) 2014-04-24 2015-10-29 Novartis Ag Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
KR20170036037A (en) 2014-07-31 2017-03-31 노파르티스 아게 Combination therapy
JP2019536812A (en) 2016-12-12 2019-12-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Nintedanib for use in methods of treating interstitial lung disease by co-administration with olodaterol
PL3558954T3 (en) 2016-12-20 2022-01-31 Inke, S.A. Improved process for the manufacture of r-6-hydroxy-8-[1-hydroxy-2-[2-(4-methoxyphenyl)-1,1-dimethylethylaminoethyl]-2h-1,4-benzoxazin-3(4h)-one hydrochloride
CN108997248B (en) * 2018-08-06 2023-08-01 上海方予健康医药科技有限公司 Crystal form B of ondarot hydrochloride and preparation method thereof
CN109096218B (en) * 2018-08-06 2020-10-27 上海方予健康医药科技有限公司 Oxydterol hydrochloride crystal form A and preparation method thereof
US20200383960A1 (en) 2019-06-10 2020-12-10 Novartis Ag Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis
JP2022547427A (en) 2019-08-28 2022-11-14 ノバルティス アーゲー Substituted 1,3-phenylheteroaryl derivatives and their use in treating disease
US11304897B2 (en) 2020-06-09 2022-04-19 Anovent Pharmaceutical (U.S.), Llc Pharmaceutical formulation containing umeclidinium bromide and vilanterol trifenatate
US11331322B1 (en) 2021-09-15 2022-05-17 Santen Pharmaceutical Co., Ltd. Medicament for preventing and/or treating dry eye

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0073505A1 (en) * 1981-09-01 1983-03-09 Boehringer Ingelheim Kg Benzo-heterocycles
US4460581A (en) * 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
EP0321864A2 (en) * 1987-12-19 1989-06-28 Boehringer Ingelheim Kg Ammonium compounds, their preparation and use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL152140A0 (en) * 2000-04-27 2003-05-29 Boehringer Ingelheim Pharma Novel, slow-acting betamimetics, a method for their production and their use as medicaments

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0073505A1 (en) * 1981-09-01 1983-03-09 Boehringer Ingelheim Kg Benzo-heterocycles
US4460581A (en) * 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
EP0321864A2 (en) * 1987-12-19 1989-06-28 Boehringer Ingelheim Kg Ammonium compounds, their preparation and use

Also Published As

Publication number Publication date
CA2506082A1 (en) 2004-06-03
EP1562603B1 (en) 2009-05-06
CN101817800A (en) 2010-09-01
ES2326878T7 (en) 2014-03-11
FR14C0049I1 (en) 2014-08-08
JP2006508140A (en) 2006-03-09
WO2004045618A3 (en) 2004-09-30
CN101735166A (en) 2010-06-16
AR041969A1 (en) 2005-06-01
CY2014032I2 (en) 2015-12-09
BRPI0316264B8 (en) 2021-05-25
AU2003285326B2 (en) 2009-06-04
PL375270A1 (en) 2005-11-28
CO5570670A2 (en) 2005-10-31
NO2014005I1 (en) 2014-03-10
TWI343812B (en) 2011-06-21
LU92433I2 (en) 2014-06-24
EA008665B1 (en) 2007-06-29
IL167900A (en) 2013-06-27
ZA200502246B (en) 2006-01-25
BE2014C016I2 (en) 2023-03-07
CN1713914A (en) 2005-12-28
CY2014032I1 (en) 2015-12-09
EP1562603A2 (en) 2005-08-17
ES2326878T3 (en) 2009-10-21
WO2004045618A2 (en) 2004-06-03
MEP53608A (en) 2011-05-10
BRPI0316264B1 (en) 2019-04-09
JP4317138B2 (en) 2009-08-19
HUS1400011I1 (en) 2022-02-28
PE20040694A1 (en) 2004-11-23
NL300650I2 (en) 2017-11-02
MY136034A (en) 2008-07-31
DE50311502D1 (en) 2009-06-18
PL212238B1 (en) 2012-08-31
UA81276C2 (en) 2007-12-25
CA2506082C (en) 2011-06-21
DK1562603T3 (en) 2009-09-07
BR0316264A (en) 2005-10-11
CY1110500T1 (en) 2015-04-29
ECSP055774A (en) 2005-11-22
TW200423943A (en) 2004-11-16
NO20052883L (en) 2005-06-14
EP2025338A1 (en) 2009-02-18
MXPA05005081A (en) 2005-07-01
RS20050361A (en) 2007-04-10
LTC1562603I2 (en) 2016-12-12
KR101092247B1 (en) 2011-12-12
AR087241A2 (en) 2014-03-12
FR14C0049I2 (en) 2015-07-24
EA200500715A1 (en) 2005-12-29
AU2003285326A1 (en) 2004-06-15
RS51607B (en) 2011-08-31
KR20050075013A (en) 2005-07-19
PT1562603E (en) 2009-06-18
HRP20050432A2 (en) 2006-06-30
NZ540661A (en) 2007-12-21
ME00354B (en) 2011-10-10
SI1562603T1 (en) 2009-10-31
EP1562603B3 (en) 2014-01-08
NO334314B1 (en) 2014-02-03
DE10253282A1 (en) 2004-05-27
ATE430569T1 (en) 2009-05-15

Similar Documents

Publication Publication Date Title
HRP20050432B1 (en) Novel medicaments for the treatment of chronic obstructive pulmonary diseases
SE0202463D0 (en) Novel compounds
MY132106A (en) New pyridazin-3(2h)-one derivatives
IS2696B (en) Substituted 2-aminotetraline for the treatment of depression
MY137133A (en) Novel compounds
SE0202462D0 (en) Novel use
WO2006005609A3 (en) Substituted oxindol derivatives and medicaments containing the same
ECSP055533A (en) BETA-AMILOID PRODUCTION REPLACED PHENYLSULFONAMIDE COMPOUNDS
SE0302324D0 (en) Novel compounds
MX2009002229A (en) Benzotriazole kinase modulators.
DE60334536D1 (en) FURYLVERBINDUNGEN
NO20051263L (en) New use of benzothiazole derivatives
SE0302486D0 (en) Novel compounds
SE0302323D0 (en) Novel compounds
ATE331711T1 (en) ANTI-INFLAMMATORY 3-ARYLTHIO-3-THIAZOLYLALKYLAMINE
RS50229B (en) Vitamin d3 analogs
MX2008001778A (en) Combination of a hypnotic agent and substituted bis aryl and heteroaryl compound and therapeutic application thereof.
SE9803773D0 (en) Compounds
SE0102641D0 (en) Novel compounds
DE60103034D1 (en) NEW PHENYLHETEROALKYLAMINE DERIVATIVES
PL369772A1 (en) Compounds that inhibit factor xa activity
SE0102639D0 (en) Novel compounds
SE9904676D0 (en) Novel compounds
DE60325079D1 (en) Naphthamide derivatives and their use
JP2004517145A5 (en)

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20181106

Year of fee payment: 16

ODRP Renewal fee for the maintenance of a patent

Payment date: 20191022

Year of fee payment: 17

ODRP Renewal fee for the maintenance of a patent

Payment date: 20201102

Year of fee payment: 18

ODRP Renewal fee for the maintenance of a patent

Payment date: 20211109

Year of fee payment: 19

ODRP Renewal fee for the maintenance of a patent

Payment date: 20221107

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20231111